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Of all blood-feeding invertebrates, few are more 
notorious than leeches (Abdualkader et al. 2013). 
Members of the phylum Annelida and subclass 
Euhirudinea, leeches predominately inhabit aquatic 
environments (Hildebrandt and Lemke 2011; Abdualkader 
et al. 2013). Of the many different species of leech, those 
that target larger vertebrates have evolved in accordance 
with their environment to be voracious ectoparasites 
(Abdualkader et al. 2013). Indeed, leeches have evolved 
sensory systems that allow them to locate their prey by 
detecting their chemical signature (Elliot 1986). This is 
facilitated primarily through sensory organs found under 
the dorsal lip, which are necessary for detecting chemical 
species produced by the body surface, such as arginine 
and sodium chloride (Elliot 1986). After the host has been 
located, a leech attaches via a sucker, makes an incision 
on the outer surface using its three jaws, and draws blood, 
which it then gathers nutrients from (Hildebrandt and 
Lemke 2011).  
     It is this ability of leeches to suck blood that was first 
utilized by humans for medicinal purposes. The first 
documentation of this is in an Egyptian illustration dating 
back to approximately 1500 B.C. (Munshi et al. 2008). 
Some physicians of the 19th century hypothesized that the 
root cause of many illnesses, such as appendicitis and 
gastroenteritis, was pooling of blood in the affected 
tissues. Bloodletting through leeching was thought to be 
an ample treatment for these and other diseases (Adams 
1998). There have been many species of leech that have 
been used to treat disease including Hirudo nipponia, 
Hirudo orientalis, and Hirudinaria manillensis (Abdualkader 
et al. 2013). However, the species that has been used 
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more than any other is the European Hirudo medicinalis 
(Abdualkader et al. 2013).  
     Despite their widespread use over the ages, it is only 
recently that researchers have begun to elucidate the true 
therapeutic functions and the molecular mechanisms by 
which leech isolates work (Hildebrandt and Lemke 2011). 
Perhaps the most notable advances are in our 
understanding of the ability of leeches to continue 
drawing blood from a victim without it clotting 
(Hildebrandt and Lemke 2011). When a blood vessel 
becomes damaged, or a leech pierces the skin and 
vasculature of an unsuspecting victim, a cascade is 
initiated in which the synthesis, activation and 
aggregation of coagulating factors occurs (Hildebrandt 
and Lemke 2011; Coughlin 2000). The protein 
prothrombin, an upstream precursor, is transformed into 
the enzyme thrombin (Coughlin 2000). Thrombin’s 
primary function is turning the molecule fibrinogen into 
smaller fibrin subunits, which link with one another to 
produce a polymer (Coughlin 2000). In combination with 
cell fragments called platelets, the fibrin polymer forms 
the clot which causes bleeding to stop (Markwardt 1994).  
     In response, leeches have evolved mechanisms to 
prevent this coagulation response in order to take a blood 
meal (Hildebrandt and Lemke, 2011). In 1884, the 
anticoagulant nature of leech extracts was initially  
characterized by Haycraft (Markwardt 1994; Salzet et al. 
2001). However, one of the main proteins responsible for 
the anticoagulant effect, hirudin, was not isolated and 
identified until the 1950s (Markwardt 1994). Initially 
hirudin’s clinical use was limited as it was difficult to find 
enough of the H. medicinalis variety to cultivate the 
necessary quantities (Markwardt 1994). After the gene 
encoding hirudin was discovered, it was cloned into E. coli, 
which allowed for mass production of hirudin (Harvey et 
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protein that acts as a direct thrombin inhibitor 
(Markwardt 1994). By stopping thrombin’s enzymatic 
function, hirudin can prevent a clot from forming 
(Markwardt 1994). In animal models, besides preventing 
clot formation, hirudin has been shown to significantly 
decrease the size of induced clots in the carotid artery and 
jugular veins. At certain doses, hirudin was able to 
completely prevent clots (Markwardt et al. 1989) While 
the formation of a clot (thrombosis) is important to 
prevent blood loss should one suffer a lesion, in many 
instances it can be deleterious (Coughlin 2000; Wadajkar 
et al. 2013). For instance, should a clot develop within the 
deep veins, it may dislodge from its place of origin, and 
travel through the circulatory system to the heart, 
resulting in a heart attack or a stroke (Wadajkar et al. 
2013).  
     Of all anticoagulants used clinically to ameliorate the 
effects of clot formation, the most common is the 
compound heparin (Greinacher and Lubenow 2003). As 
opposed to hirudin, heparin inhibits thrombin indirectly by 
binding to and further activating the protein anti-
thrombin, whose role is to inhibit thrombin’s catalytic 
activity (Hirsh et al. 2001). Despite its widespread use, 
heparin administration is coupled with serious side 
effects. One of the most detrimental side effects is 
heparin-induced thrombocytopenia, which is a  reduction 
in the number of platelets following heparin use 
(Greinacher and Lubenow 2003). Because of this, hirudin 
has been evaluated as an alternative treatment (Topol et 
al. 1994). It should be noted that while adverse reactions 
following hirudin use are rare, severe allergic reactions 
have been reported in 0.015% of patients (Greinacher and 
Warkentin 2008). Whether or not this is due specifically to 
hirudin administration is relatively unknown.  
Additionally, hirudin use can cause excessive bleeding 
which may be exacerbated by kidney dysfunction 




(Greinacher and Warkentin 2008; Markwardt 1994). 
However, patients treated with hirudin have been shown 
to have excessive bleeding less often than those treated 
with heparin (Stone et al. 2008).  
     Myocardial infarction (heart attack) is responsible for 
nearly 16,000 deaths in Canada per year. It results when 
there is not enough blood flowing to the heart muscle, 
and as a result, the lack of oxygen brings about cell death 
(Heart and Stroke 2015; University of Maryland Medical 
Center 2014). One of the events that commonly precedes 
myocardial infarction is unstable angina (Falk 1985). 
Unstable angina is heart pain that results from a lack of 
blood flowing to the heart (Braunwald 1989; Maseri et al. 
1999). While the exact mechanism of its occurrence is still 
being investigated, it is suggested by some that, when 
atherosclerotic plaque within a coronary artery breaks, 
the thrombin cascade is initiated, and a clot forms, 
narrowing the diameter of the blood vessels and 
restricting blood flow (Maseri et al. 1999).  In a study by 
Topol et al. (1994), the effects of hirudin on patients with 
unstable angina pectoris were examined. In the study, 
patients were administered either heparin or hirudin. 
Following treatment, the mean coronary artery cross 
sectional area was found to increase more in patients 
treated with hirudin compared to the heparin control 
group. This indicates that hirudin was able to reduce 
clotting to a greater extent (Topol et al. 1994). 
Furthermore, there was a smaller incidence of myocardial 
infarction in those treated with hirudin compared to those 
treated with heparin (Topol et al. 1994).  
     In a study by Stone et al. (2008), patients with elevated 
ST-segments, an indicator of a blocked coronary artery, 
underwent Primary Percutaneous Coronary Intervention 
(Pierard 2007; Stone et al. 2008). Patients were either 
administered hirudin or heparin. It was found that 
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complications after treatment compared to the heparin 
group. This included less excessive bleeding as well as 
reduced thrombocytopenia. The mortality rate among the 
hirudin patients was also significantly lower than those 
treated with heparin (Stone et al. 2008).  
     Clots can also travel to the cerebral vasculature, 
resulting in a stroke (Wadajkar et al. 2013). Approximately 
14,000 strokes in Canada each year are fatal (Heart and 
Stroke Foundation 2014). Hirudin has shown promise in 
reducing the severity of physiological injury and cognitive 
impairment in animal models of stroke (Karabiyikoglu et 
al. 2004). While hirudin has yet to be applied on a large 
scale clinically for stroke, in a study by Harrigan et al. 
(2004), intra-arterial hirudin injection was able to 
ameliorate thrombosis within a cerebral artery, allowing 
for a reduction in motor deficits caused by the blockage.  
     Coagulation has also been shown to play a role in the 
development of cancer (Hara et al. 1980). Cancer cells and 
platelets can bind together and anneal to the vasculature. 
This interaction can greatly contribute to the spread of 
cancer across the body particulary when platelets bind to 
cancer cells that are travelling freely in the blood stream 
(Li 2016).  As a result, some leech extracts have been 
tested for anti-oncogenic properties (Gasic et al. 1983). In 
a study by Esumi et al. (1991) skin cancer cells were found 
to increase blood coagulation in vitro. When hirudin was 
administered clotting ceased. On this basis it has been 
proposed that this may be one avenue by which leech 
derivatives, particularly hirudin, could be used to clinically 
ameliorate metastasis (Esumi et al. 1991). Hirudin has also 
been shown to hinder aggregation of mesothelioma cells 
(Bastida et al. 1983). Mesothelioma is a variant of cancer 
that commonly originates and develops in the pleural 
membrane of the lung or the pericardium of the heart 
(Remon et al. 2015). This may be a result of coming into 
contact with asbestos (Remon et al. 2015).  




     The anticoagulant nature of leech derivatives is not 
exclusive to hirudin (Gasic et al. 1983). In a study by Gasic 
et al. (1983), leech saliva extract was found to dramatically 
decrease the size and prevalence of lung tumors in vivo. 
Another protein isolated from leech saliva, Lj-RGD3, has 
been shown to significantly reduce cell growth and blood 
vessel development (Wang et al. 2010). This plays an 
important role in the development of metastasis (Wang et 
al. 2010). In a later study by Jin et al. (2012), Lj-RGD3 was 
also found to halt growth and invasiveness of drug 
resistant breast cancer cells. 
     Despite these promising findings, leech extracts and 
hirudin have not been tested in humans as cancer 
treatments. However, heparin, whose function is similar 
to that of hirudin, has been tested.  For instance, in a 
study by Altinbas et al. (2004), patients with small cell 
lung cancer were either given chemotherapy in addition 
to heparin or only chemotherapy. Tumor progression was 
evaluated after 18 weeks of treatment. Cancer 
progression was found to be reduced in 69% of patients 
treated with chemotherapy and heparin compared to only 
43 % of patients within the chemotherapy control group 
(Altinbas et al. 2004). The  length of patient survival 
following treatment was also significantly higher in the 
heparin and chemotherapy group compared to those 
patients treated exclusively with chemotherapy (Altinbas 
et al. 2004). Therefore, it is possible that hirudin could be 
used to treat cancer in a similar way without the 
deleterious side effects accompanied by heparin use 
(Greinacher and Lubenow 2003).  
     To avoid being detected by the host while attaching 
and feeding, leeches may have evolved mechanisms to 
reduce sensation and subsequent pain (Hildebrant and 
Lemke 2011). This is supported by the findings of 
Michalsen et al. (2003). In the study, patients with 
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of diclofenac, an anti-inflammatory, or leeches to the 
knee (Michalsen et al. 2003). Their reported levels of pain 
were examined (Michalsen et al. 2003). Following 
treatment, patients in the leech therapy group had a 
greater reduction in knee pain compared to patients 
treated with diclofenac. The patients in the leech therapy 
group also reported having less joint stiffness and 
improved utility of the knee (Michalsen et al. 2003).     
     Some have suggested that derivatives of leech saliva 
may be a valuable intervention following 
neurodegeneration. Recent studies have documented the 
usefulness of compounds, such as eglin C, bdellastasin, 
and destabilase, in significantly increasing the rate of 
spinal neurite outgrowth in vitro. Another derivative, 
high-molecular-weight bdellin, was found to increase this 
outgrowth by 60 percent (Chalisova et al. 2001). Hirudin 
has also been evaluated in treating patients with mild to 
moderate progression of Alzheimer’s disease (Li et al. 
2012). In a recent investigation, patients treated with both 
Donepezil and hirudin showed cognitive decline to a 
significantly lesser extent compared to the Donepezil 
control group. A greater improvement in ability to 
perform daily activities was also noted compared to 
patients treated exclusively with Donepezil (Li et al. 2012).   
     While there have been many compounds isolated from 
the saliva of leeches, such as hirudin, continuing research 
has led to the discovery of many others (Hildebrandt and 
Lemke 2011). These molecules have shown tremendous 
efficacy in ameliorating a wide variety of ailments from 
myocardial infarction to cognitive decline (Topo et al. 
1994; Li et al. 2012). Furthermore, although clinical trials 
have yet to commence, leech-derived substances have 
shown promise in cancer treatment (Esumi et al. 1991). 
Leech evolution tied to vertebrate hosts has allowed them 
to develop mechanisms to become efficient predators 
(Hildebrandt and Lemke 2011). While leeches may 




predate and harm humans, the very biological 
mechanisms involved in this interaction has allowed 
humans to use the compounds involved for therapeutic 
purposes, and we can expect that, as research continues, 
even more pharmaceutically effective drugs derived from 
leeches will become available (Abdualkader et al. 2013).   
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